BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
PharmAbbie is developing drugs targeted at the pet market based on existing human formulations. The company is concentrating on therapeutic categories including pain and inflammation, infections, diarrhea, dermatology, and cardiovascular problems, intended to provide safe, efficacious and easy-to-administer drugs to improve the quality of life of companion animals and their guardians.
PharmAbbie
Groton, CT
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.